United States 119th Congress Status: In Committee Bipartisan · 19 R · 16 D · 1 I cosponsors

S 545 — Combating Illicit Xylazine Act

Last action — Placed on Senate Legislative Calendar under General Orders. Calendar No. 372.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced February 12, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

Prognosis

Advancing 42% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 36 sponsors

    1 primary, 35 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 3 parties (19 R · 16 D · 1 I) — cross-party backing.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Bill Text

What changed in the latest version

183 added · 20 removed

Plain-language change summary

The changes to S. 545 removed the provisions establishing a short title and definitions for the term "xylazine." Additionally, the amendments clarified that nothing in this title or the amendments requires an ultimate user of xylazine to register under the Controlled Substances Act to possess it. This matters because it specifies legal conditions under which individuals can possess xylazine without needing to register, potentially easing compliance for users.

→
Previous
Latest
545 Introduced in Senate (IS)] <DOC> 119th CONGRESS 1st Session S.
545 Reported in Senate (RS)] <DOC> Calendar No.
372 119th CONGRESS 2d Session S.
Lujan, and Mr.
Lujan, Mr.
Wicker) introduced the following bill;
Wicker, Mr.
which was read twice and referred to the Committee on the Judiciary _______________________________________________________________________ A BILL To prohibit certain uses of xylazine, and for other purposes.
Gallego, Mr.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1.
Tillis, Mr.
Fetterman, Mr.
Bennet, Ms.
Lummis, Mr.
Budd, Mr.
King, Mr.
Justice, Mr.
Crapo, Mr.
McCormick, Mr.
Lankford, Mrs.
Moody, Mrs.
Blackburn, Mr.
Cornyn, Mr.
Durbin, and Mr.
Cruz) introduced the following bill;
which was read twice and referred to the Committee on the Judiciary April 15 (legislative day, April 14), 2026 Reported by Mr.
Grassley, with an amendment [Strike out all after the enacting clause and insert the part printed in italic] _______________________________________________________________________ A BILL To prohibit certain uses of xylazine, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, <DELETED>SECTION 1.
SHORT TITLE.</DELETED> <DELETED> This title may be cited as the ``Combating Illicit Xylazine Act''.</DELETED> <DELETED>SEC.
2.
DEFINITIONS.</DELETED> <DELETED> (a) In General.--In this title, the term ``xylazine'' has the meaning given the term in paragraph (60) of section 102 of the Controlled Substances Act, as added by subsection (b) of this section.</DELETED> <DELETED> (b) Controlled Substances Act.--Section 102 of the Controlled Substances Act (21 U.S.C.
802) is amended by adding at the end the following:</DELETED> <DELETED> ``(60) The term `xylazine' means the substance xylazine, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible.''.</DELETED> <DELETED>SEC.
3.
ADDING XYLAZINE TO SCHEDULE III.</DELETED> <DELETED> Schedule III of section 202(c) of the Controlled Substances Act (21 U.S.C.
812) is amended by adding at the end the following:</DELETED> <DELETED> ``(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of xylazine.''.</DELETED> <DELETED>SEC.
4.
AMENDMENTS.</DELETED> <DELETED> (a) Amendment.--Section 102 of the Controlled Substances Act (21 U.S.C.
802) is amended by striking paragraph (27) and inserting the following:</DELETED> <DELETED> ``(27)(A) Except as provided in subparagraph (B), the term `ultimate user' means a person who has lawfully obtained, and who possesses, a controlled substance for the use by the person or for the use of a member of the household of the person or for an animal owned by the person or by a member of the household of the person.</DELETED> <DELETED> ``(B)(i) In the case of xylazine, other than for a drug product approved under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
355), the term `ultimate user' means a person--</DELETED> <DELETED> ``(I) to whom xylazine was dispensed by-- </DELETED> <DELETED> ``(aa) a veterinarian registered under this Act;
or</DELETED> <DELETED> ``(bb) a pharmacy registered under this Act pursuant to a prescription of a veterinarian registered under this Act;
and</DELETED> <DELETED> ``(II) who possesses xylazine for--</DELETED> <DELETED> ``(aa) an animal owned by the person or by a member of the household of the person;</DELETED> <DELETED> ``(bb) an animal under the care of the person;</DELETED> <DELETED> ``(cc) use in government animal-control programs authorized under applicable Federal, State, Tribal, or local law;
or</DELETED> <DELETED> ``(dd) use in wildlife programs authorized under applicable Federal, State, Tribal, or local law.</DELETED> <DELETED> ``(ii) In this subparagraph, the term `person' includes-- </DELETED> <DELETED> ``(I) a government agency or business where animals are located;
and</DELETED> <DELETED> ``(II) an employee or agent of an agency or business acting within the scope of their employment or agency.''.</DELETED> <DELETED> (b) Facilities.--An entity that manufactures xylazine, as of the date of enactment of this Act, shall not be required to make capital expenditures necessary to install the security standard required of schedule III of the Controlled Substances Act (21 U.S.C.
et seq.) for the purposes of manufacturing xylazine.</DELETED> <DELETED> (c) Labeling.--The requirements related to labeling, packaging, and distribution logistics of a controlled substance in schedule III of section 202(c) of the Controlled Substances Act (21 U.S.C.
812(c)) shall not take effect for xylazine until the date that is 1 year after the date of enactment of this Act.</DELETED> <DELETED> (d) Practitioner Registration.--The requirements related to practitioner registration, inventory, and recordkeeping of a controlled substance in schedule III of section 202(c) of the Controlled Substances Act (21 U.S.C.
Show all 76 changed rows (36 more)
Previous
Latest
812(c)) shall not take effect for xylazine until the date that is 60 days after the date of enactment of this Act.
A practitioner that has applied for registration during the 60-day period beginning on the date of enactment of this Act may continue their lawful activities until such application is approved or denied.</DELETED> <DELETED> (e) Manufacturer Transition.--The Food and Drug Administration and the Drug Enforcement Administration shall facilitate and expedite the relevant manufacturer submissions or applications required by the placement of xylazine on schedule III of section 202(c) of the Controlled Substances Act (21 U.S.C.
812(c)).</DELETED> <DELETED> (f) Clarification.--Nothing in this title, or the amendments made by this title, shall be construed to require the registration of an ultimate user of xylazine under the Controlled Substances Act (21 U.S.C.
801 et seq.) in order to possess xylazine in accordance with subparagraph (B) of section 102(27) of that Act (21 U.S.C.
802(27)), as added by subsection (a) of this section.</DELETED> <DELETED>SEC.
5.
ARCOS TRACKING.</DELETED> <DELETED> Section 307(i) of the Controlled Substances Act (21 U.S.C.
827(i)) is amended--</DELETED> <DELETED> (1) in the matter preceding paragraph (1)-- </DELETED> <DELETED> (A) by inserting ``or xylazine'' after ``gamma hydroxybutyric acid'';</DELETED> <DELETED> (B) by inserting ``or 512'' after ``section 505'';
and</DELETED> <DELETED> (C) by inserting ``respectively,'' after ``the Federal Food, Drug, and Cosmetic Act,'';
and</DELETED> <DELETED> (2) in paragraph (6), by inserting ``or xylazine'' after ``gamma hydroxybutyric acid''.</DELETED> <DELETED>SEC.
6.
SENTENCING COMMISSION.</DELETED> <DELETED> Pursuant to its authority under section 994(p) of title 28, United States Code, the United States Sentencing Commission shall review and, if appropriate, amend its sentencing guidelines, policy statements, and official commentary applicable to persons convicted of an offense under section 401 of the Controlled Substances Act (21 U.S.C.
841) or section 1010 of the Controlled Substances Import and Export Act (21 U.S.C.
960) to provide appropriate penalties for offenses involving xylazine that are consistent with the amendments made by this title.
In carrying out this section, the Commission should consider the common forms of xylazine as well as its use alongside other scheduled substances.</DELETED> <DELETED>SEC.
7.
REPORT TO CONGRESS ON XYLAZINE.</DELETED> <DELETED> (a) Initial Report.--Not later than 18 months after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report on the prevalence of illicit use of xylazine in the United States and the impacts of such use, including--</DELETED> <DELETED> (1) where the drug is being diverted;</DELETED> <DELETED> (2) where the drug is originating;
and</DELETED> <DELETED> (3) whether any analogues to xylazine, or related or derivative substances, exist and present a substantial risk of abuse.</DELETED> <DELETED> (b) Additional Report.--Not later than 4 years after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report updating Congress on the prevalence and proliferation of xylazine trafficking and misuse in the United States.</DELETED> SECTION 1.
(a) In General.--In this title, the term ``xylazine'' has the meaning given the term in paragraph (60) of section 102 of the Controlled Substances Act, as added by subsection (b) of this section.
(a) In General.--In this Act-- (1) the term ``practitioner'' has the meaning given the term under section 102 of the Controlled Substances Act (21 U.S.C.
802);
and (2) the term ``xylazine'' has the meaning given the term in paragraph (61) of section 102 of the Controlled Substances Act, as added by subsection (b) of this section.
``(60) The term `xylazine' means the substance xylazine, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible.''.
``(61) The term `xylazine' means the substance xylazine, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible.''.
(f) Clarification.--Nothing in this title, or the amendments made by this title, shall be construed to require the registration of an ultimate user of xylazine under the Controlled Substances Act (21 U.S.C.
(f) Clarification.--Nothing in this Act, or the amendments made by this Act, shall be construed to require the registration of an ultimate user of xylazine under the Controlled Substances Act (21 U.S.C.
and (2) in paragraph (6), by inserting ``or xylazine'' after ``gamma hydroxybutyric acid''.
and (2) in paragraph (6), by inserting ``and xylazine'' after ``gamma hydroxybutyric acid''.
960) to provide appropriate penalties for offenses involving xylazine that are consistent with the amendments made by this title.
960) to provide appropriate penalties for offenses involving xylazine that are consistent with the amendments made by this Act.
(a) Initial Report.--Not later than 18 months after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report on the prevalence of illicit use of xylazine in the United States and the impacts of such use, including-- (1) where the drug is being diverted;
(a) Control Report.-- (1) In general.--Not later than 30 days after the date of enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Secretary of Health and Human Services, shall submit to Congress a report with an assessment of the factors listed in section 201(c) of the Controlled Substances Act (21 U.S.C.
811(c)) for xylazine, which includes a scientific and medical evaluation and recommendations from the Secretary of Health and Human Services and a law enforcement and abuse evaluation by the Drug Enforcement Administration.
(2) Requirements.--The report required under paragraph (1) shall-- (A) include the full text of the scientific and medical evaluation and recommendations regarding whether xylazine should be controlled as a controlled substance, submitted by the Secretary of Health and Human Services to the Attorney General pursuant to section 201(b) of the Controlled Substances Act (21 U.S.C.
811(b)) on or before December 31, 2025;
and (B) be published on the websites of the Department of Health and Human Services and the Department of Justice.
(b) Initial Report.--Not later than 18 months after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report on the prevalence of illicit use of xylazine in the United States and the impacts of such use, including-- (1) where the drug is being diverted;
(b) Additional Report.--Not later than 4 years after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report updating Congress on the prevalence and proliferation of xylazine trafficking and misuse in the United States.
(c) Additional Report.--Not later than 4 years after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report updating Congress on the prevalence and proliferation of xylazine trafficking and misuse in the United States.
<all>
Calendar No.
372 119th CONGRESS 2d Session S.
545 _______________________________________________________________________ A BILL To prohibit certain uses of xylazine, and for other purposes.
_______________________________________________________________________ April 15 (legislative day, April 14), 2026 Reported with an amendment
⬇ Download PDF
View plain text versions (2)

Action History

  1. Introduced in Senate

  2. Read twice and referred to the Committee on the Judiciary.

  3. Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

  4. Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.

  5. Placed on Senate Legislative Calendar under General Orders. Calendar No. 372.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 35 co-sponsors · 511 not signed on

Sponsors (1)

Co-sponsors (35)

Not signed on (511)

511 members have not signed on to this bill.

Show all 511 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors S 545?
S 545 is sponsored by Cortez Masto, Catherine (Democratic), Grassley, Chuck (Republican), Hassan, Margaret Wood (Democratic), Gillibrand, Kirsten E. (Democratic), Hyde-Smith, Cindy (Republican), Cantwell, Maria (Democratic), Scott, Rick (Republican), Shaheen, Jeanne (Democratic), Klobuchar, Amy (Democratic), Britt, Katie Boyd (Republican), Capito, Shelley Moore (Republican), Young, Todd (Republican), Kelly, Mark (Democratic), Kaine, Tim (Democratic), Risch, James E. (Republican), Rosen, Jacky (Democratic), Blumenthal, Richard (Democratic), Luján, Ben Ray (Democratic), Wicker, Roger F. (Republican), Gallego, Ruben (Democratic), Tillis, Thomas (Republican), Fetterman, John (Democratic), Bennet, Michael F. (Democratic), Lummis, Cynthia M. (Republican), Budd, Ted (Republican), King, Angus S., Jr. (Independent), Justice, James C. (Republican), Crapo, Mike (Republican), McCormick, David (Republican), Lankford, James (Republican), Moody, Ashley (Republican), Blackburn, Marsha (Republican), Cornyn, John (Republican), Durbin, Richard J. (Democratic), Cruz, Ted (Republican), and Merkley, Jeff (Democratic).
What is the current status of S 545?
This bill is in committee in the Senate. Introduced February 12, 2025. It must pass committee before a floor vote.
Where can I track S 545?
Track S 545 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 545

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 545

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →